Bristol-Myers Squibb
275 S Bryn Mawr Ave, F18,
Bryn Mawr
PA
19010
United States
Tel: 269366-0681
193 articles about Bristol-Myers Squibb
-
Secarna Pharmaceuticals' Strategic Partner Evotec Achieves Programme Designation in Neuroscience Collaboration with Bristol Myers Squibb
4/12/2022
Secarna Pharmaceuticals GmbH & Co. KG has reached another programme designation within its neuroscience collaboration with Bristol Myers Squibb (NYSE:BMY) triggering a payment of US$ 16 m to Evotec.
-
European Medicines Agency Validates Bristol Myers Squibb’s Application for Opdivo (nivolumab) with Chemotherapy as Neoadjuvant Treatment for Resectable Non-Small Cell Lung Cancer
3/29/2022
European Medicines Agency Validates Bristol Myers Squibb’s Application for Opdivo (nivolumab) with Chemotherapy as Neoadjuvant Treatment for Resectable Non-Small Cell Lung Cancer.
-
Bristol Myers Squibb Announces New Prescription Drug User Fee Act Goal Date for Reblozyl® (luspatercept-aamt) Supplemental Biologics License Application
3/25/2022
Bristol Myers Squibb Announces New Prescription Drug User Fee Act Goal Date for Reblozyl ® (luspatercept-aamt) Supplemental Biologics License Application.
-
FDA Approves First LAG 3 Inhibitor Antibody Opdualag For Metastatic Melanoma
3/22/2022
Opdualag is a fixed dose combination of nivolumab (Opdivo) and relatlimab (LAG-3 inhibitor) developed by Bristol Myers Squibb. It is first LAG-3 inhibitor which has been granted approval by US FDA on March 18, 2022 for the management of patients with unresectable or metastatic melanoma.
-
Bristol Myers Squibb to Demonstrate the Strength of its Growing Cardiovascular Portfolio at the American College of Cardiology’s 71st Annual Scientific Session
3/21/2022
Bristol Myers Squibb to Demonstrate the Strength of its Growing Cardiovascular Portfolio at the American College of Cardiology’s 71st Annual Scientific Session.
-
Bristol Myers Squibb and Nektar Announce Update on Phase 3 PIVOT IO-001 Trial Evaluating Bempegaldesleukin (BEMPEG) in Combination with Opdivo (nivolumab) in Previously Untreated Unresectable or Metastatic Melanoma
3/14/2022
Bristol Myers Squibb and Nektar Announce Update on Phase 3 PIVOT IO-001 Trial.
-
Bristol Myers Squibb to Report Results for First Quarter 2022 on April 29, 2022
3/11/2022
Bristol Myers Squibb (NYSE:BMY) will announce results for the first quarter of 2022 on Friday, April 29, 2022.
-
Bristol Myers Squibb Announces Positive Topline Results from Phase 3 VALOR-HCM Trial, Evaluating Mavacamten in Patients with Obstructive Hypertrophic Cardiomyopathy
2/16/2022
Bristol Myers Squibb (NYSE: BMY) today announced that VALOR-HCM, the Phase 3 randomized, double-blind, placebo-controlled study evaluating mavacamten in adults with symptomatic obstructive hypertrophic cardiomyopathy (obstructive HCM) who are eligible for septal reduction therapy (SRT), met its primary endpoint at Week 16.
-
Bristol Myers Squibb Enters Into $5 Billion Aggregate Accelerated Share Repurchase Agreements
2/9/2022
Bristol Myers Squibb (NYSE:BMY) today announced that it has entered into accelerated share repurchase (ASR) transactions under agreements with Morgan Stanley & Co. LLC, Barclays Bank PLC, Citibank, N.A. and JPMorgan Chase Bank, N.A., (collectively, the “ASR Agreements”) to repurchase, in aggregate, $5 billion of Bristol Myers Squibb common stock.
-
ADDING and REPLACING Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2021
2/4/2022
ADDING and REPLACING Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2021.
-
Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2021
2/4/2022
Bristol Myers Squibb (NYSE:BMY) today reports results for the fourth quarter and full year of 2021, which reflect strong sales driven by robust commercial execution and significant advancement of the company’s pipeline that further progressed the company’s portfolio renewal.
-
Bristol Myers Squibb Receives Positive CHMP Opinion for CAR T Cell Therapy Breyanzi (lisocabtagene maraleucel) for Relapsed or Refractory DLBCL, PMBCL and FL3B
1/28/2022
Bristol Myers Squibb Receives Positive CHMP Opinion for CAR T Cell Therapy Breyanzi (lisocabtagene maraleucel) for Relapsed or Refractory DLBCL, PMBCL and FL3B.
-
Prellis Biologics Announces Collaboration and License Agreement with Bristol Myers Squibb
1/13/2022
Prellis Biologics, Inc. (Prellis), a Bay Area biotechnology company, announced today that it has entered into a multi-target drug discovery collaboration and licensing agreement with Bristol Myers Squibb.
-
ArsenalBio Announces Expansion of Collaboration with Bristol Myers Squibb to Advance T Cell Therapy in Solid Tumors
1/10/2022
Arsenal Biosciences, Inc. today announced that Bristol Myers Squibb (NYSE:BMY) has exercised an option to initiate a new program, expanding its strategic collaboration with ArsenalBio to discover and advance next-generation T cell therapies for the treatment of solid tumors.
-
Bristol Myers Squibb to Present at J.P. Morgan’s 40th Annual Healthcare Conference
1/4/2022
Bristol Myers Squibb to Present at J.P. Morgan’s 40th Annual Healthcare Conference.
-
Bristol Myers Squibb to Report Results for Fourth Quarter 2021 on February 4, 2022
12/17/2021
Bristol Myers Squibb (NYSE:BMY) will announce results for the fourth quarter of 2021 on Friday, February 4, 2022. During a conference call at 8 a.m. ET on February 4, 2022, company executives will review financial results and address inquiries from investors and analysts.
-
Bristol Myers Squibb Announces Dividend Increase and Additional $15 Billion Share Repurchase Authorization
12/13/2021
Bristol Myers Squibb (NYSE: BMY) today announced that on December 10, 2021, its Board of Directors approved an increase in the quarterly dividend and authorized an additional multi-year share repurchase program.
-
U.S. Food and Drug Administration Accepts for Priority Review supplemental Biologics License Application for Reblozyl® (luspatercept-aamt) in Adults with Non-Transfusion Dependent (NTD) Beta Thalassemia
12/3/2021
U.S. Food and Drug Administration Accepts for Priority Review supplemental Biologics License Application for Reblozyl ® (luspatercept-aamt).
-
Bristol Myers Squibb’s Applications for Deucravacitinib for the Treatment of Moderate to Severe Plaque Psoriasis Accepted by U.S. Food and Drug Administration and Validated by European Medicines Agency
11/29/2021
Applications supported by positive results from the pivotal Phase 3 POETYK-PSO clinical trial program demonstrating superior efficacy of deucravacitinib over Otezla ® (apremilast) and placebo in treating adults with moderate to severe plaque psoriasis.
-
Bristol Myers Squibb Receives European Commission Approval of Zeposia (ozanimod) for use in Adults with Moderately to Severely Active Ulcerative Colitis
11/23/2021
Bristol Myers Squibb Receives European Commission Approval of Zeposia (ozanimod) for use in Adults with Moderately to Severely Active Ulcerative Colitis.